ReviewGastro hep advances2026
Unveiling Genital Crohn's Disease: Clinical Complications, Diagnosis, and Treatment, a Comprehensive Review of Case Reports.
Review in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genital Crohn's disease (GCD) is an infrequent extraintestinal manifestation of Crohn's disease characterized by ulceration, pain, edema, and erythema in the anogenital area. GCD poses significant diagnostic and management challenges, mainly because there are no standardized clinical protocols. This review analyzed 20 case reports and series from 1983 to 2024, focusing on patients with GCD. The databases used for this search were PubMed, Scopus, and Google Scholar. The most common presentation in male patients was genital edema or swelling, seen in 88.9% of cases. Pain was the main presentation in 71.9% of cases among female patients. Several complications were reported, including rectovaginal and enterovaginal fistulas, tubo-ovarian abscesses, and penile involvement. The diagnosis was made based on clinical evaluation, which was supported by laboratory tests, physical examinations, imaging, and endoscopic procedures. Histological examinations of biopsied genital ulcers demonstrated non-caseating granulomatous inflammation; however, this finding was observed in only 50% of patients. Moreover, pelvic magnetic resonance imaging is highlighted as a crucial diagnostic tool. The most common form of treatment is pharmacological therapy. Corticosteroids, immunosuppressants, and tumor necrosis factor-alpha inhibitors are the most frequently used drugs. A total of 14 studies reported that corticosteroids administered via intravenous and oral routes resulted in a notable reduction in disease severity. The tumor necrosis factor-alpha inhibitors adalimumab and infliximab showed notable efficacy. New therapies such as carbon laser therapy and autologous stem cell transplantation showed promising outcomes in refractory cases. Surgical procedures are reserved for refractory or complicated cases. This review highlights that medical management with corticosteroids, immunomodulators, and biologics remains the cornerstone of treatment for GCD, with surgery playing a role in refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.